Supreme Court Denies Pharma Fish Oil Monopoly

Amarin wanted an import ban on certain fish oil supplements.
In a win for consumer access to natural products, the Supreme Court has denied Amarin’s final petition for appeal in the company’s effort to corner the market on fish oil.
In 2017, Amarin asked the US International Trade Commission (ITC) to ban the importation of omega-3 dietary supplements composed mainly of EPA, known for its anti-inflammatory properties. The ITC sensibly decided not to pursue the issue, and Amarin appealed all the way to the Supreme Court.
We’re happy the issue has been resolved, as it would have been extraordinary if Amarin was able to win a monopoly on fish oil. Although Amarin has received FDA-approval for its Vascepa fish oil drug, fish oil was marketed years before those clinical trials began, meaning the supplement can stay on the market.

8 comments

  2. Why can’t the Homeopathic industry gather together in a class action suit against the FDA’s proposed ban on Compounding Pharmacies producing homeopathic supplements, once the ban goes into effect? Homeopathy has been around far longer that omega-3 dietary supplements, and it has a safe history of helping a lot of people.

  3. It’s about time the right decision has been made.. Consult need protection against people and corporations like this

  6. Finally, a win for consumers. It really is sickening how the FDA has become another processor of corporate greed and monopoly. They have lost credibility as an agency meant to do good for the health of Americans.

  7. Hooray! We’re finally getting support for what we believe in. We have to look at the results not the wishes of big Pharmas. It took them a long time to get here with the fish oil.

  8. I’m sure they are planing their next move. How to lobby Congress for favorable laws. Drug companies have no moral compass, no conscience. It’s not about finding a drug to help you, it’s about finding a drug to make them rich.

Comments are closed.